Acadia Pharmaceuticals Inc. is on track to file for US Food and Drug Administration approval for a potential new indication for Nuplazid (pimavanserin) for the treatment of dementia-related psychosis sometime in 2020. The company announced on 9 September that a Phase III trial testing pimavanserin in the patient population will be stopped early based on a positive interim efficacy analysis.
The early good news surprised investors, with the company's stock jumping 75% to open the day at $41.75. Some investors...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
